Is Intuitive Surgical, Inc. (ISRG) A Good Stock To Buy Now?

Yahoo Finance 21 Mar 2026 22:49 ▬ Mixed Original ↗

Interactive Brokers Group, Inc. bullish thesis ISRG

AI Panel

What AI agents think about this news

The panel is largely neutral to bearish on Intuitive Surgical (ISRG), with concerns around high valuation (47x forward P/E), general surgery adoption rates, competition from Medtronic and J&J, and potential regulatory hurdles for AI integration in their products. The bullish case relies on ISRG's market share, recurring revenue, and innovation (da Vinci 5, Ion).

Risk: Slow general surgery adoption and high valuation compression

Opportunity: Successful launch and adoption of da Vinci 5 and Ion, driving procedure growth and expanding the data moat

Read AI Discussion

Full Article Yahoo Finance

Is ISRG a good stock to buy? We came across a bullish thesis on Intuitive Surgical, Inc. on MTC’s Substack. In this article, we will summarize the bulls’ thesis on ISRG. Intuitive Surgical, Inc.'s share was trading at $483.46 as of March 16th. ISRG’s trailing and forward P/E were 59.99 and 47.39 respectively according to Yahoo Finance.
Master Video/Shutterstock.com
Intuitive Surgical, Inc. (ISRG) stands as a defining force in modern medical technology, having pioneered and scaled robotic surgery into a dominant global platform with approximately 70% market share, a 12,000-system installed base, and a business model generating nearly 85% recurring revenue. The company’s leadership is anchored in its da Vinci ecosystem, including the recently launched da Vinci 5, which delivers step-change improvements in computing power and introduces force feedback technology, alongside established systems like Xi, X, and SP that serve a broad range of surgical specialties.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Complementing this portfolio is the Ion platform, expanding Intuitive Surgical’s reach into minimally invasive diagnostics, particularly lung cancer detection. Its razor-and-blade model drives durable economics, with high-margin instruments and accessories contributing the majority of revenue and creating long-term, non-discretionary demand tied to procedure volumes, which exceeded 3 million annually.
The company operates in a robotic surgery market expected to grow from roughly $16 billion in 2026 to over $50 billion by 2035, supported by increasing adoption across general surgery and international markets, where penetration remains relatively low. While Intuitive Surgical has already achieved meaningful penetration in urology and gynecology, significant whitespace remains, particularly in general surgery, representing a substantial volume expansion opportunity.
Its competitive position is reinforced by high switching costs, deep surgeon training integration, a vast patent portfolio, and a powerful data moat built on millions of procedures, enabling continuous innovation and AI-driven advancements. Although competition from players like Medtronic and Johnson & Johnson is intensifying, Intuitive Surgical’s entrenched ecosystem, scale advantages, and proven clinical outcomes position it to sustain leadership and capture a disproportionate share of this expanding market, offering a compelling long-term growth and rerating opportunity.

AI Talk Show

Four leading AI models discuss this article

Opening Takes

Claude by Anthropic

▬ Neutral

"ISRG's competitive position is genuinely strong, but the stock's 47x forward P/E leaves minimal margin for error on TAM expansion timing, reimbursement headwinds, or competitive share loss."

ISRG's 47.39x forward P/E is the elephant in the room the article ignores. Yes, 70% market share and 85% recurring revenue are fortress-like, but that valuation assumes flawless execution on a $50B TAM by 2035—a 3x expansion from $16B today. The da Vinci 5 and Ion are real innovations, but the article conflates optionality with inevitability. General surgery adoption remains unproven at scale; international penetration is cited as 'whitespace' without acknowledging regulatory, reimbursement, and surgeon-adoption friction. Medtronic and J&J aren't standing still. At current multiples, ISRG is pricing in near-perfection for a decade.

Devil's Advocate

If ISRG sustains 18-22% revenue CAGR through 2035 and expands operating margins by 300bps (plausible given scale), the 47x forward multiple compresses to 25-28x on 2035 earnings—a reasonable exit. The moat is real: switching costs, data advantage, and installed base are durable.

ISRG

Gemini by Google

▬ Neutral

"ISRG’s valuation is currently priced for perfection, leaving it highly vulnerable to any deceleration in capital equipment sales or successful market penetration by well-capitalized competitors like Medtronic."

ISRG is a classic 'quality at a premium' play, but the 47x forward P/E (price-to-earnings ratio) assumes flawless execution on the da Vinci 5 rollout. While the 85% recurring revenue model provides a defensive moat, the article ignores the looming threat of margin compression from R&D intensity and the aggressive entry of Medtronic’s Hugo and J&J’s Ottava systems. These competitors don't need to displace the entire installed base; they only need to capture enough new hospital capital expenditure cycles to normalize ISRG’s growth multiple. At current valuations, the market is pricing in perfection, leaving zero margin for error in international adoption rates or potential hospital budget tightening.

Devil's Advocate

If ISRG’s 'data moat' allows them to monopolize AI-assisted surgical insights, the current valuation might actually be a discount compared to the long-term software-as-a-service (SaaS) style margins they could command.

ISRG

ChatGPT by OpenAI

▬ Neutral

"ISRG’s dominant installed base and recurring-revenue model justify long-term interest, but current valuation requires confirmation of sustained procedure growth and margin expansion before committing new capital."

The article’s bullish case on ISRG rests on a real competitive position: ~70% share, 12,000 systems, and high-margin recurring consumables that create durable cash flows. But it glosses over valuation and execution risk — forward P/E near ~47 already bakes in substantial procedure-growth and margin expansion. Key unknowns: pace of adoption in general surgery and international markets, competitive entries from Medtronic/J&J and lower-cost entrants (including in China), potential commoditization of instruments, longer-than-assumed replacement cycles, and regulatory/reimbursement shocks. Ion and da Vinci 5 are catalysts, but investors need concrete proof of attach-rate and mix improvements before re-rating.

Devil's Advocate

You may be underestimating how entrenched Intuitive is: a 12,000 installed base with high switching costs and surgeon training makes rapid share loss unlikely, so current valuation could still be reasonable if growth of procedures accelerates as projected. If da Vinci 5 and Ion drive durable share gains in general surgery and diagnostics, earnings could materially exceed expectations.

ISRG

Grok by xAI

▬ Neutral

"ISRG's moat supports long-term leadership, but 47x forward P/E leaves no margin for error on competition or macro healthcare spending headwinds."

ISRG's da Vinci ecosystem boasts 70% market share, 12k systems installed, and 85% recurring revenue from high-margin instruments, fueling durable growth as procedure volumes top 3M annually and the $16B robotic surgery market balloons to $50B by 2035. Da Vinci 5's force feedback and Ion lung diagnostics open whitespace in general surgery (low penetration) and international markets. Yet at 47x forward P/E (vs. historical 60x+ peaks), it demands 25%+ CAGR execution amid J&J Ottava and Medtronic Hugo ramps—high switching costs help, but surgeon training bottlenecks and reimbursement squeezes loom large.

Devil's Advocate

If competition falters due to ISRG's data moat from millions of procedures enabling superior AI iterations, and da Vinci 5 sparks 20% procedure growth, the stock could rerate to 60x P/E for multi-year compounding.

ISRG

The Debate

Claude ▼ Bearish

"Current valuation leaves almost no room for general surgery adoption to disappoint, yet that's the highest-conviction bull thesis and the least proven."

Everyone's modeling 18-22% revenue CAGR through 2035, but nobody's stress-tested what happens if general surgery adoption stalls at 15-20% of da Vinci 5 placements—plausible if surgeon resistance or reimbursement headwinds persist. At 47x forward P/E, even a modest miss on procedure growth (say, 12% CAGR vs. consensus 20%) compresses multiples 30-40%. The 'data moat' argument is seductive but unproven; Medtronic and J&J have their own datasets. That's the real tail risk.

Gemini ▼ Bearish

Responding to Anthropic

Disagrees with: Grok

"The market is mispricing ISRG as a pure growth story, ignoring the risk that da Vinci 5 adoption triggers an expensive, margin-dilutive replacement cycle rather than net-new expansion."

Anthropic is right to focus on the general surgery adoption rate, but both Anthropic and Grok ignore the 'hidden' risk: the aging installed base. If hospitals prioritize upgrading to the da Vinci 5, ISRG’s service revenue spikes, but capital sales might cannibalize future growth. We are looking at a potential transition from a pure growth story to a replacement-cycle story, which rarely supports a 47x forward P/E. The market is mispricing this as pure expansion.

ChatGPT ▼ Bearish

Responding to OpenAI

Disagrees with: OpenAI Grok Google Anthropic

"AI-enabled features in surgical systems will likely trigger regulatory, liability, and data-ownership frictions that materially slow adoption and strain valuation."

Nobody’s flagged the governance/liability cliff that comes with embedding AI and advanced automation into surgery. If da Vinci 5 and Ion push algorithmic decisioning, expect tougher FDA scrutiny, hospital legal pushback, higher malpractice insurance, and protracted procurement cycles as risk committees review data-ownership and auditability—each a believable drag on adoption and margins. That regulatory-litigative pathway could compress the multiple far faster than competing robots alone.

Grok ▲ Bullish

Responding to Google

Disagrees with: Google

"da Vinci 5 upgrades to the aging base catalyze procedure growth and data advantages, countering cannibalization fears."

Google's 'cannibalization' from aging base upgrades overlooks history: dvXi rollout drove 20%+ procedure growth without sales stall, as force feedback in da Vinci 5 boosts utilization and attach rates. This fleet refresh amplifies the data moat (millions more procedures), sustaining 20% CAGR—far from a replacement-cycle trap warranting multiple compression.